Phase 2 Study of Oral ENV-294 for Adults With Moderate-to-Severe Atopic Dermatitis Evaluating Safety and Effectiveness Over 12 Weeks

What this Trial Is About

Researchers are evaluating the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The study aims to find out if ENV-294 can reduce the severity and area affected by atopic dermatitis and to monitor any medical problems participants may experience while taking the drug. This is a phase 2, randomized, double-blind, placebo-controlled trial sponsored by Enveda Therapeutics. Participants will take either ENV-294 or a placebo once daily by mouth for 12 weeks. Those in the treatment arm will receive ENV-294 tablets, while those in the placebo arm will receive matching tablets without the active drug. Participants will visit the clinic every 2 to 4 weeks for checkups and tests during the treatment period. After 12 weeks, participants will return to the clinic for a final study visit at about week 16. During the study, participants will keep a diary to record their symptoms and study drug intake. Researchers will assess the severity and extent of atopic dermatitis, monitor adverse events, and evaluate patient-reported outcomes and pharmacokinetics of ENV-294 from baseline through week 12. Safety and effectiveness will be closely monitored throughout the trial, with a total participation duration of approximately 16 weeks.

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis